Review

Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19

Volume: 4 Number: 3 December 30, 2022
EN

Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19

Abstract

The novel coronavirus disease 2019 (COVID-19) emerged in China in late December 2019 and quickly spread to many countries around the world. Antiviral drugs are candidate treatments for the treatment of COVID-19. Molnupiravir, the first oral antiviral drug, is a drug with anti-RNA polymerase activity and is currently being used for the treatment of COVID-19 patients. In this review, we aimed to discuss the mechanism of action, safety, efficacy and clinical studies of molnupiravir in the treatment of patients with COVID-19.

Keywords

References

  1. 1. Jayk Bernal, A. et al. N. English J. Med. https://doi.org/10.1056/NEJMoa2116044 (2021).
  2. 2. Woolhouse ME, Brierley L., McCaffery C., Lycett S. Evaluation of the epidemic potential of RNA and DNA viruses. Emergency Infection Dis. 2016; 22 :2037–2044. [ PMC free article ] [ PubMed ] [ Google Scholar ]
  3. 3. Shu B., Gong P. Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation. Proc Natl Acad Sci USA A. 2016; 113 :E4005–E4014. [ PMC free article ] [ PubMed ] [ Google Scholar ]
  4. 4. Gorbalenya AE, Pringle FM, Zeddam JL, Luke BT, Cameron CE, Kalmakoff J., Hanzlik TN, Gordon KH, Ward VK Palm subdomain-based active site is internally in viral RNA-dependent RNA polymerases of an ancient lineage. allowed. . J Mol Biol. 2002; 324 :47-62. [ PMC free article ] [ PubMed ] [ Google Scholar ]
  5. 5. De Clercq E., Li G. Antiviral drugs approved in the last 50 years. Clin Microbiol Rev. 2016; 29 :695–747. [ PMC free article ] [ PubMed ] [ Google Scholar ]
  6. 6. Jordheim LP, Durantel D., Zoulim F., Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Pharmaceutical Diskov. 2013; 12 :447-464. [ PubMed ] [ Google Scholar ]
  7. 7. Jordan PC, Stevens SK, Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir Chemistry Chemotherapy. 2018; 26 [ PMC free article ] [ PubMed ] [ Google Scholar ]
  8. 8. 17. Giry C., Roquebert B., Li-Pat-Yuen G., Gasque P., Jaffar-Bandjee MC Enhanced detection of genus-specific Alphavirus using a generic TaqMan® assay. BMC Microbiology. 2017; 17 :164. [ PMC free article ] [ PubMed ] [ Google Scholar ]

Details

Primary Language

English

Subjects

Emergency Medicine

Journal Section

Review

Publication Date

December 30, 2022

Submission Date

May 1, 2022

Acceptance Date

November 6, 2022

Published in Issue

Year 2022 Volume: 4 Number: 3

APA
Sarıdaş, A. (2022). Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19. Eurasian Journal of Critical Care, 4(3), 116-118. https://doi.org/10.55994/ejcc.1112050
AMA
1.Sarıdaş A. Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19. Eurasian j Crit Care. 2022;4(3):116-118. doi:10.55994/ejcc.1112050
Chicago
Sarıdaş, Ali. 2022. “Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19”. Eurasian Journal of Critical Care 4 (3): 116-18. https://doi.org/10.55994/ejcc.1112050.
EndNote
Sarıdaş A (December 1, 2022) Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19. Eurasian Journal of Critical Care 4 3 116–118.
IEEE
[1]A. Sarıdaş, “Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19”, Eurasian j Crit Care, vol. 4, no. 3, pp. 116–118, Dec. 2022, doi: 10.55994/ejcc.1112050.
ISNAD
Sarıdaş, Ali. “Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19”. Eurasian Journal of Critical Care 4/3 (December 1, 2022): 116-118. https://doi.org/10.55994/ejcc.1112050.
JAMA
1.Sarıdaş A. Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19. Eurasian j Crit Care. 2022;4:116–118.
MLA
Sarıdaş, Ali. “Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19”. Eurasian Journal of Critical Care, vol. 4, no. 3, Dec. 2022, pp. 116-8, doi:10.55994/ejcc.1112050.
Vancouver
1.Ali Sarıdaş. Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19. Eurasian j Crit Care. 2022 Dec. 1;4(3):116-8. doi:10.55994/ejcc.1112050